THE TREATMENT OF MULTIPLE SYSTEM ATROPHY PARKINSONIAN VARIANT (MSA-P)

Clinical trials for THE TREATMENT OF MULTIPLE SYSTEM ATROPHY PARKINSONIAN VARIANT (MSA-P) explained in plain language.

Never miss a new study

Get alerted when new THE TREATMENT OF MULTIPLE SYSTEM ATROPHY PARKINSONIAN VARIANT (MSA-P) trials appear

Sign up with your email to follow new studies for THE TREATMENT OF MULTIPLE SYSTEM ATROPHY PARKINSONIAN VARIANT (MSA-P), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Brain stem cell injection trial launches for rare Parkinson's-Like disease

Disease control Not yet recruiting

This early-stage study tests whether injecting special stem cells into the brain is safe for people with a rare, severe movement disorder called MSA-P. Only 3 participants will receive the treatment, and the main goal is to check for serious side effects within the first month. T…

Matched conditions: THE TREATMENT OF MULTIPLE SYSTEM ATROPHY PARKINSONIAN VARIANT (MSA-P)

Phase: PHASE1 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 13:01 UTC

THE TREATMENT OF MULTIPLE SYSTEM ATROPHY PARKINSONIAN VARIANT (MSA-P)

Get alerted when new THE TREATMENT OF MULTIPLE SYSTEM ATROPHY PARKINSONIAN VARIANT (MSA-P) trials appear

Brain stem cell injection trial launches for rare Parkinson's-Like disease